In contrast, moderate neuronal overexpression of wild-type ADAM10 in an AD mouse model showed increased sAPPα secretion, reduced Aβ peptide and plaque formation, and alleviated impaired long-term potentiation and cognitive deficits, indicating that activation of ADAM10 could perform a therapeutic activity for AD [53]. Here, ADAM10 is linked to Alzheimer disease.